Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01): PAR-17-003
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as “assays”) to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as “markers” or “biomarkers”) for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention.
NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131): 11/27/2016
NIH Requests Information on Strategies for NIH Data Management, Sharing, and Citation.
This Request for Information (RFI) seeks public comments on data management and sharing strategies and priorities in order to consider: (1) how digital scientific data generated from NIH-funded research should be managed, and to the fullest extent possible, made publicly available; and, (2) how to set standards for citing shared data and software.
Open comment period through December 29, 2016
Welcome to the Cancer Diagnosis Program!
The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.
For more information about the Cancer Diagnosis Program and its Branches, please click here.